Capricor Therapeutics (CAPR) Aperçu de l'action
Capricor Therapeutics, Inc. est une société de biotechnologie au stade clinique qui se consacre au développement de thérapies cellulaires et exosomiques transformatrices pour le traitement de la dystrophie musculaire de Duchenne (DMD) et d'autres maladies dont les besoins médicaux ne sont pas satisfaits aux États-Unis. Plus de détails
| Score flocon de neige | |
|---|---|
| Évaluation | 4/6 |
| Croissance future | 5/6 |
| Performances passées | 0/6 |
| Santé financière | 5/6 |
| Dividendes | 0/6 |
Récompenses
Analyse des risques
CAPR Community Fair Values
Create NarrativeSee what 57 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$58
FV
88.5% sous-évalué décote intrinsèque275
users have viewed this narrative3users have liked this narrative
0users have commented on this narrative
12users have followed this narrative
Capricor Therapeutics, Inc. Concurrents
Historique des prix et performances
| Historique des cours de bourse | |
|---|---|
| Prix actuel de l'action | US$6.65 |
| Plus haut sur 52 semaines | US$40.37 |
| Plus bas sur 52 semaines | US$2.96 |
| Bêta | 0.53 |
| Variation sur 1 mois | -65.79% |
| Variation sur 3 mois | -75.30% |
| Variation sur 1 an | -13.64% |
| Variation sur 3 ans | -13.75% |
| Variation sur 5 ans | 64.60% |
| Évolution depuis l'introduction en bourse | -84.17% |
Nouvelles et mises à jour récentes
Recent updates
Mise à jour du récit • Aug 11
CAPR: Post AdCom Regulatory Outcome Will Drive 2026 Upside Potential
Capricor Therapeutics now carries a sharply reduced analyst price target of about $4.38, down from roughly $49.44, as analysts factor in the negative deramiocel AdCom vote, heightened FDA approval concerns, higher perceived risk, and lower projected profitability and P/E multiples. Analyst Commentary Recent research on Capricor Therapeutics has shifted sharply after the deramiocel advisory committee outcome, with most firms now focused on regulatory risk, legal overhangs, and reduced earnings potential.Seeking Alpha • Jul 28
Capricor Therapeutics: Downgrading To Sell As FDA Doubts Mount
Summary Capricor Therapeutics is downgraded to Sell after FDA briefing materials cast doubt on deramiocel’s efficacy in DMD cardiomyopathy. FDA highlighted that HOPE-3’s positive endpoints were only achieved after post-unblinding SAP changes, undermining statistical validity. With deramiocel’s approval in jeopardy and the rest of the pipeline in early stages, CAPR now resembles a preclinical/Phase 1 company. Despite $278.6M cash and no major debt, dilution risk looms as Capricor’s commercial prospects dim and market cap reflects higher uncertainty. Read the full article on Seeking AlphaMise à jour du récit • Jul 27
CAPR: July FDA Panel Vote Will Determine Bullish 2026 Approval Path
Capricor Therapeutics' analyst fair value estimate has been reduced from $54.67 to $49.44, as analysts factor in sharply lower price targets following critical FDA briefing documents on deramiocel, multiple downgrades to Neutral ratings, and increased concern that current data and statistical protocols may not support approval in its present form. Analyst Commentary Recent Street research on Capricor Therapeutics highlights a sharp reassessment of risk around deramiocel ahead of the upcoming FDA advisory committee meeting, with price targets and ratings moving in response to concerns over data integrity, statistical methods, and regulatory pushback.
Nouveau récit • Jul 12
The Exosome Pioneer: Why Capricor (CAPR) is Poised for an August FDA Breakthrough
Prologue: Witnessing the Exosome Revolution in Clinical Practice As a veterinarian actively running a clinic in 2026, I have seen firsthand the disruptive power of exosome technology. Last year, I introduced an 'exosome ice-needling injection machine' at my hospital to treat some of the most stubborn conditions in small animals.
Mise à jour du récit • Jun 15
CAPR: August FDA Decision On Duchenne Therapy Will Drive Long Term Upside Potential
Capricor Therapeutics' analyst price target has been cut by $5, to $38 from $43, as analysts factor in the removal of an expected $80 million milestone payment linked to the NS Pharma dispute and a later modeled U.S. launch for Deramiocel. Analyst Commentary Bullish analysts are recalibrating their models around the NS Pharma dispute and timing of the Deramiocel U.S. launch, yet some still see meaningful potential tied to upcoming regulatory and monetization events.
Mise à jour du récit • Jun 01
CAPR: FDA Decision And HOPE-3 Data Will Drive Bullish Repricing
Analysts have trimmed their average price target on Capricor Therapeutics by about $1.60 to roughly $39.40. This reflects adjustments for the removed $80m milestone and a later modeled Deramiocel U.S. launch, while still factoring in upcoming FDA decisions and related catalysts.Mise à jour du récit • May 15
CAPR: August PDUFA Decision Will Shape Duchenne Treatment Adoption Outlook
Narrative Update: Capricor Therapeutics Analyst Price Target Shift The analyst price target for Capricor Therapeutics has been reduced by $5 to $38, as analysts factor in the removal of an expected $80 million milestone payment and a later modeled U.S. launch for Deramiocel following the company’s legal action against NS Pharma. Analyst Commentary Recent Street research around Capricor Therapeutics has shifted from purely optimistic toward a more balanced stance, as bullish analysts factor in both regulatory progress for Deramiocel and the impact of the company’s legal action against NS Pharma.Mise à jour du récit • Apr 29
CAPR: August PDUFA Cardiac Data Will Drive Bullish 2026 Approval Setup
Narrative Update: Capricor Therapeutics The updated analyst price target framework for Capricor Therapeutics moves from a prior fair value of $50.80 to $54.67. This reflects analysts' use of higher projected revenue growth, wider profit margins and a higher future P/E multiple following recent positive deramiocel data, FDA review progress and a series of target increases across the Street.Mise à jour du récit • Apr 15
CAPR: August PDUFA Decision Will Drive Bullish Duchenne Thesis
Analysts have lifted their average price targets on Capricor Therapeutics into a $41 to $63 range, supported by recent FDA progress on deramiocel for Duchenne muscular dystrophy, additional positive Phase 3 HOPE-3 data, and updated cash and review timelines that feed into modest tweaks to discount rate, revenue growth, profit margin, and future P/E assumptions in the valuation model. Analyst Commentary Bullish analysts are largely framing recent volatility in Capricor Therapeutics as a short-term shakeout rather than a shift in the long-term story.Mise à jour du récit • Apr 01
CAPR: August PDUFA And HOPE 3 Readout Will Shape Bullish Case
Analysts have lifted their blended price target on Capricor Therapeutics to $63, supported by higher targets from several firms. These firms point to recent FDA milestones for deramiocel in Duchenne muscular dystrophy, additional Phase 3 HOPE-3 data, and updated PDUFA timing as key drivers behind their refreshed assumptions.Mise à jour du récit • Mar 18
CAPR: August PDUFA Decision And HOPE 3 Data Will Drive Bullish Outlook
Narrative Update on Capricor Therapeutics The analyst fair value estimate for Capricor Therapeutics has moved from $62.00 to $63.00, reflecting updated Street research that points to higher price targets tied to recent FDA progress for deramiocel in Duchenne muscular dystrophy and supportive Phase 3 HOPE-3 data. Analyst Commentary Recent Street research has been broadly constructive on Capricor Therapeutics, with bullish analysts highlighting regulatory milestones for deramiocel in Duchenne muscular dystrophy and updated Phase 3 HOPE-3 data as key drivers behind their views.Mise à jour du récit • Mar 03
CAPR: HOPE 3 Data And BLA Resubmission Will Drive Bullish 2026 Approval Path
Analysts now place a slightly higher implied value on Capricor Therapeutics, with their updated price target moving to $62.00. This is supported by modest tweaks to the discount rate, revenue growth assumptions, and long-term profit margin and P/E inputs.Mise à jour du récit • Feb 17
CAPR: HOPE-3 Regulatory Progress And Capital Raise Will Drive Bullish Repricing
Analysts have kept their $41.00 price target for Capricor Therapeutics unchanged, citing only minor model adjustments such as slightly different discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Capricor provided a regulatory update on its Biologics License Application for Deramiocel in Duchenne muscular dystrophy, with the FDA requesting the full Phase 3 HOPE-3 clinical study report and supporting data to address a Complete Response Letter, without asking for additional clinical studies or new patient data.Mise à jour du récit • Feb 03
CAPR: Phase 3 Duchenne Cardiac Results Will Shape Bullish 2026 Approval Path
Narrative Update The analyst price target for Capricor Therapeutics has moved from about US$44.56 to US$50.80, with analysts pointing to expectations around Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy and updated modeling assumptions as key drivers of the change. Analyst Commentary Recent Street research points to a change in how some analysts are framing risk and potential reward around Capricor Therapeutics, especially with Phase 3 HOPE-3 data for Deramiocel in Duchenne muscular dystrophy cardiomyopathy expected in Q4.Mise à jour du récit • Jan 20
CAPR: HOPE 3 Cardiac Outcome Data Will Shape Bullish Mid 2026 Approval Path
The analyst price target for Capricor Therapeutics has increased from $12 to $13, as analysts incorporate updated assumptions for Deramiocel approval in Duchenne muscular dystrophy cardiomyopathy and anticipated Phase 3 HOPE-3 cardiac outcome data. Analyst Commentary Bullish analysts are framing the price target move to US$13 as a reflection of updated expectations around Deramiocel in Duchenne muscular dystrophy cardiomyopathy rather than a broad shift in the overall story.Mise à jour du récit • Jan 06
CAPR: HOPE-3 Duchenne Cardiac Data Will Drive Bullish Repricing
Analysts have lifted their fair value estimate for Capricor Therapeutics from $12.00 to $41.00 per share, citing updated assumptions around Deramiocel approval prospects in Duchenne muscular dystrophy cardiomyopathy, following recent Street research and price target revisions. Analyst Commentary Recent Street commentary around Capricor Therapeutics has centered on expectations for Deramiocel in Duchenne muscular dystrophy cardiomyopathy, with valuation work closely tied to regulatory outcomes and clinical readouts for the Phase 3 HOPE-3 trial anticipated in Q4.Mise à jour du récit • Dec 19
CAPR: Mid 2026 Approval Path Will Drive HOPE 3 Cardiac Catalyst Narrative
Analysts have sharply increased their price target for Capricor Therapeutics, effectively more than doubling fair value from approximately $29 to about $62. They cite higher projected revenue growth, a dramatic improvement in long term profit margins, a more normalized future earnings multiple, and growing confidence that positive HOPE-3 data could support regulatory flexibility and keep a potential Deramiocel approval on track for mid 2026.Mise à jour du récit • Dec 05
CAPR: Phase 3 Duchenne Cardiac Data Will Drive 2026 Approval Hopes
Analysts have sharply raised their price target on Capricor Therapeutics, with the modeled fair value estimate climbing from about $20.60 to roughly $44.56 per share. They cite stronger expected revenue growth, significantly improved profit margins, and increasing confidence that positive HOPE-3 Phase 3 data could support Deramiocel approval for Duchenne muscular dystrophy cardiomyopathy on an accelerated mid 2026 timeline.Article d’analyse • Nov 05
We're Not Very Worried About Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...Article d’analyse • Sep 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 30% Price Plummet
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 30...Article d’analyse • Jun 24
Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) 25% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) shares are down a considerable 25...Article d’analyse • May 16
Here's Why We Think Capricor Therapeutics, Inc.'s (NASDAQ:CAPR) CEO Compensation Looks Fair
Key Insights Capricor Therapeutics to hold its Annual General Meeting on 22nd of May CEO Linda Marbán's total...Article d’analyse • May 09
Capricor Therapeutics, Inc. (NASDAQ:CAPR) May Have Run Too Fast Too Soon With Recent 26% Price Plummet
Unfortunately for some shareholders, the Capricor Therapeutics, Inc. ( NASDAQ:CAPR ) share price has dived 26% in the...
Nouveau récit • May 03
FDA Priority Review And NS Pharma Partnership Will Empower Deramiocel
FDA priority review of deramiocel and partnership with NS Pharma could drive significant revenue growth and market penetration.Rendement pour les actionnaires
| CAPR | US Biotechs | US Marché | |
|---|---|---|---|
| 7D | 72.7% | 0.5% | 0.6% |
| 1Y | -13.6% | 35.8% | 20.1% |
Rendement vs Industrie: CAPR a sous-performé le secteur US Biotechs qui a rapporté 35.8 % au cours de l'année écoulée.
Rendement vs marché: CAPR a sous-performé le marché US qui a rapporté 20.1 % au cours de l'année écoulée.
Volatilité des prix
| CAPR volatility | |
|---|---|
| CAPR Average Weekly Movement | 28.6% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.3% |
| 10% least volatile stocks in US Market | 3.1% |
Cours de l'action stable: Le cours de l'action de CAPR a été volatil au cours des 3 derniers mois par rapport au marché US.
Volatilité au fil du temps: La volatilité hebdomadaire de CAPR a diminué de 56% à 29% au cours de l'année écoulée, mais reste supérieure à 75 % des actions de US.
À propos de l'entreprise
| Fondée | Salariés | PDG | Site web |
|---|---|---|---|
| 2005 | 231 | Linda Marbán | www.capricor.com |
Capricor Therapeutics, Inc. est une société de biotechnologie au stade clinique qui se consacre au développement de thérapies cellulaires et exosomiques transformatrices pour le traitement de la dystrophie musculaire de Duchenne (DMD) et d'autres maladies dont les besoins médicaux ne sont pas satisfaits aux États-Unis. Son principal produit candidat est le Deramiocel, une cellule allogène dérivée de la cardiosphère, qui est en phase 3 d'essai clinique pour le traitement de la DMD. L'entreprise développe également un vaccin à base de protéines Exosome, qui est en phase d'essai préclinique pour traiter le SRAS-CoV-2 ; StealthX Exosome Platform, et le programme de plateforme d'exosomes consiste en des exosomes modifiés pour le développement de vaccins et de thérapies et est en phase d'essai préclinique.
Capricor Therapeutics, Inc. Résumé des fondamentaux
| CAPR statistiques fondamentales | |
|---|---|
| Capitalisation boursière | US$386.62m |
| Bénéfices(TTM) | -US$129.42m |
| Recettes(TTM) | n/a |
0.0x
Ratio P/S-3.0x
Ratio P/ELe site CAPR est-il surévalué ?
Voir Juste valeur et analyse de l'évaluationBénéfices et recettes
| CAPR compte de résultat (TTM) | |
|---|---|
| Recettes | US$0 |
| Coût des recettes | US$99.73m |
| Marge brute | -US$99.73m |
| Autres dépenses | US$29.68m |
| Les revenus | -US$129.42m |
Derniers bénéfices déclarés
Jun 30, 2026
Prochaine date de publication des résultats
s/o
| Résultat par action (EPS) | -2.23 |
| Marge brute | 0.00% |
| Marge bénéficiaire nette | 0.00% |
| Ratio dettes/capitaux propres | 0% |
Quelles ont été les performances à long terme de CAPR?
Voir les performances historiques et les comparaisonsAnalyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/08/17 16:06 |
| Cours de l'action en fin de journée | 2026/08/14 00:00 |
| Les revenus | 2026/06/30 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github ; nous proposons également des guides sur la façon d’utiliser nos rapports et des tutoriels sur YouTube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Capricor Therapeutics, Inc. est couverte par 10 analystes. 10 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Matthew Venezia | Alliance Global Partners |
| Madison Wynne El-Saadi | B. Riley Securities, Inc. |
| Kristen Kluska | Cantor Fitzgerald & Co. |